Serum YKL-40 as a potential biomarker of inflammation in psoriasis. (2nd January 2018)

• Record Type: Journal Article
• Authors: Baran, Anna; Myśliwiec, Hanna; Szterling-Jaworowska, Malgorzata; Kiluk, Paulina; Świderska, Magdalena; Flisiak, Iwona
• Is Part Of: Journal of dermatological treatment. Volume 29:Number 1(2018)
• Page Start: 19
• Page End: 23
• Publication Date: 2018-01-02
• Subjects: Psoriasis -- YKL-40 -- cardiovascular disease -- atherosclerosis -- topical treatment -- anthralin; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2017.1330529
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: Objective: YKL-40 is an inflammatory glycoprotein associated with atherosclerosis, cardiovascular disease, diabetes or metabolic syndrome which are common comorbidities in psoriasis. The aim of the study was to assess serum YKL-40 level in psoriasis and elucidate possible associations with disease activity, inflammatory or metabolic parameters and treatment. Methods: A total of 37 individuals with active plaque-type psoriasis and 15 healthy controls were enrolled. Blood samples were collected before and after 2 weeks of therapy. Serum YKL-40 concentrations were evaluated by enzyme-linked immunosorbent assay (ELISA). The results were correlated with Psoriasis Area and Severity Index (PASI), body mass index (BMI), inflammatory and biochemical markers, lipid profile and topical therapy. Results: Median YKL-40 serum levels were significantly increased in psoriatic patients in comparison to the controls ( p < .0001). No significant correlations between investigated protein and metabolic parameters as BMI ( p = .19), glucose ( p = .32) nor lipids levels were found. Significant positive relation with CRP ( p = .003) or alanine aminotransferase ( p = .04) and no correlation with PASI ( p = .2) were noted. Serum YKL-40 level remained unchanged ( p = .5) after topical treatment, despite clinical improvement. Conclusions: YKL-40 might be a biomarker of psoriasis and inflammation in psoriatic patients, but not a reliable indicator of metabolic conditions, severity of psoriasis nor efficacy of the treatment.